Products, inhalers, and characteristics of long-acting β2 adrenoceptor agonists
| Active Ingredient | Indication | Inhaler | Dose | Pharmacological Profile | Clinical Summary |
|---|---|---|---|---|---|
| Aformoterol | Chronic treatment of COPD | Nebulizer | 15 µg BID | β2 adrenoceptor agonist rapid onset <5 min and duration <12 h | Only indicated for chronic use not for acute rescue |
| Formoterol | Chronic treatment of asthma and COPD | DPI Nebulizer | 12 μg/capsule BID 20 μg BID | β2 adrenoceptor agonist rapid onset <5 min and duration <12 h | Chronic treatment of asthma and COPD |
| Chronic treatment of COPD Neither for acute relief | |||||
| Indacaterol | Chronic treatment of COPD | DPI | 75 µg o.d. | β2 adrenoceptor agonist rapid onset <5 min and long duration >24 h | Chronic treatment of COPD not for acute relief |
| Olodaterol | Chronic treatment of COPD | Soft mist | 2.5 µg/2 actuations o.d. | β2 adrenoceptor agonist rapid onset <5 min and long duration >24 h | Chronic treatment of COPD not for acute relief |
| Salmeterol | Chronic treatment of asthma and COPD | DPI pMDI | 50 µg/capsule BID 21 μg/puff; two puffs BID | β2 adrenoceptor agonist slow onset >30 min and long duration >12 h | Chronic treatment of COPD not for acute relief |